Atypical Femur Fracture: Identification and Management | Atypical Femoral Fracture: An Update
Includes a Live Web Event on 04/11/2026 at 2:00 PM (EDT)
Atypical Femur Fracture: Identification and Management
E. Michael Lewiecki, MD, FACP, FACE, CCD
Saturday, April 11, 2026, 2:00pm to 2:30 pm Eastern Time (NY/USA)
Description
AFFs are associated with some osteoporosis treatments and may occur without any treatment. The risk of AFF for most patients is very low and can be minimized with appropriate care. This presentation will address strategies for early recognition AFF, treatment of incomplete and complete AFF, and management of osteoporosis after AFF.
Atypical Femoral Fracture: An Update
WuQiang Fan, MD, PhD
Saturday, April 11, 2026, 2:30pm to 3:00 pm Eastern Time (NY/USA)
Objectives
In this session, we will:
- Review the risks, epidemiological patterns, and clinical features of atypical femoral fractures (AFFs).
- Discuss differential management of AFF linked to bisphosphonate or denosumab therapy, including areas of uncertainty.
- Evaluate the clinical implications of current AFF knowledge in the context of anti-osteoporosis pharmacotherapy.
E. Michael Lewiecki, MD, FACP, FACE, CCD
Director
New Mexico Clinical Research & Osteoporosis Center, Inc.
E. Michael Lewiecki, MD, CCD, FACP, FACE, FASBMR, is Director of New Mexico Clinical Research & Osteoporosis Center and Director of Bone Health ECHO at University of New Mexico Health Sciences Center in Albuquerque, NM. His is a consultant in osteoporosis and metabolic bone disease, supervisor and interpreter of bone density studies, and an educator with a special interest in the evaluation and treatment of osteoporosis and metabolic bone diseases. He has been principal investigator for many osteoporosis clinical trials and is author of over 300 publications in peer-reviewed medical journals, as well as books, book chapters, and online publications on osteoporosis. Dr. Lewiecki is past-president of the International Society for Clinical Densitometry (ISCD) and current president of the Osteoporosis Foundation of New Mexico (OFNM). He is an editor for Osteoporosis International, and is on the editorial boards of the Journal of Bone and Mineral Research and the Journal of Clinical Densitometry. He has received national and international awards that include the 2021 “Dr. John P. Bilezikian ISCD Global Leadership Award” and the 2021 “Lawrence G. Raisz Memorial Lecture Award” with the Bone Health & Osteoporosis Foundation. Dr. Lewiecki is the program director of the annual Santa Fe Bone Symposium, the flagship activity of the OFNM.
WuQiang Fan, MD, PhD
Director of Fracture Liaison Service, Assistant Professor of Medicine
Massachusetts General Hospital, Harvard Medical School
Dr. WuQiang Fan (pronounced as “Wu-Chiang Fan”) earned his medical degree from Zhejiang University School of Medicine in China. He subsequently completed his PhD in molecular biology at Kyushu University in Japan, where he investigated steroid hormone receptor signaling and transcriptional regulation. He then pursued postdoctoral research on diabetes and insulin signaling at the University of California, San Diego School of Medicine, before undertaking internal medicine residency training at Drexel University College of Medicine. In 2016, he began his endocrinology fellowship at Massachusetts General Hospital (MGH), where he remained on faculty following graduation. His clinical interests focus on metabolic bone disease and diabetes. He currently serves as Director of the MGH Fracture Liaison Service and Fracture Secondary Prevention Program, and as one of the Associate Program Directors of the MGH Endocrinology Fellowship Training Program. He is an Assistant Professor of Medicine at Harvard Medical School.